Total Lymphocyte Count, Hemoglobin, and Delayed-Type Hypersensitivity as Predictors of Death and AIDS Illness in HIV-1-Infected Women Receiving Highly Active Antiretroviral Therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 4, 2004, Pages 383-392

  Anastos, Kathryn ^a,j   Shi, Quihu ^b   French, Audrey L ^c   Levine, Alexandra ^d   Greenblatt, Ruth M ^e   Williams, Carolyn ^f   DeHovitz, Jack ^g   Delapenha, Robert ^h   Hoover, Donald R ⁱ  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c Jr Hospital of Cook County   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g SUNY DOWNSTATE MEDICAL CENTER   (United States)

^h HOWARD UNIVERSITY HOSPITAL   (United States)

ⁱ RUTGERS UNIVERSITY   (United States)

^j MONTEFIORE MEDICAL CENTER   (United States)

more..

Author keywords

Disease progression; Highly active antiretroviral therapy; HIV; Survival; Total lymphocyte count

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CANDIDA ANTIGEN; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TETANUS TOXOID;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLONAL ANERGY; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG INDICATION; FATALITY; FEMALE; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; SEROPREVALENCE; SKIN TEST; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HUMANS; HYPERSENSITIVITY, DELAYED; LYMPHOCYTE COUNT; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 1542618447     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200404010-00008     Document Type: Article

References (37)

1. Anastos K, Barron Y, Greenblatt R, et al. Risk of disease progression and death in HIV infected women initiating highly active antiretroviral therapy at different stages of disease. Arch Intern Med. 2002;162:1973-1980.
2. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001;286:2560-2567.
3. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
4. Panel on clinical practices for treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002;137:381-443.
5. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2001;2:276-313.
6. Post FA, Wood R, Maartens G. CD4 and total lymphocyte counts as predictors of HIV disease progression. Q J Med. 1996;89:505-508.
7. Kumarasamy N, Mahajan AP, Flanigan TP, et al. Total lymphocyte count (TLC) is a useful tool for the timing of opportunistic infection prophylaxis in India and other resource-constrained countries. J Acquir Immune Defic Syndr. 2002;31:378-383.
8. Gange SJ, Lau B, Phair J, et al. Rapid declines in total lymphocyte count and hemoglobin in HIV infection begin at CD4 lymphocyte counts that justify antiretroviral therapy. AIDS. 2003;17:119-121.
9. Kumarasamy N, Flanigan TP, Mahajan AP, et al. Monitoring HIV treatment in the developing world. Lancet Infect Dis. 2002;2:656-657.
10. Badri M, Wood R. Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:541-545.
11. Flanigan T, Mahajan A, Kumarasamy N, et al. Total lymphocyte count as a surrogate for CD4 count to initiate and monitor HAART in resource-limited countries. Paper presented at: Ninth Conference on Retroviruses and Opportunistic Infections; February 2002; Seattle, WA.
12. Spacek LA, Griswold M, Quinn TC, et al. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS. 2003;17:1311-1317.
13. Chronic HIV care with ARV therapy-integrated management of adult and adolescent illness: interim guidelines for first level facility health workers. World Health Organization. December 2003. Available at: http://www.who.int/entity/3by5/publications/documents/en/IMAI_Chronic_HIV.pdf. Accessed February 12, 2004.
14. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women. Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28-35.
15. Berhane K, Gange SJ, Masri-Lavine L, et al. Impact of highly active antiretroviral therapy on anemia, and relationship between anemia and survival in a large cohort of HIV infected women. Women's Interagency HIV Study. (Submitted)
16. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir Immune Defic Syndr. 1998;19:29-33.
17. Semba RD, Shah N, Klein RS, et al. Highly active antiretroviral therapy associated with improved anemia among HIV-infected women. Aids Patient Care STDS. 2001;15:473-480.
18. Birx DL, Brundage J, Larson K, et al. The prognostic utility of delayed type hypersensitivity skin testing in the evaluation of HIV infected patients. J Acquir Immune Defic Syndr. 1993;6:1248-1257.
19. Gordin FM, Hartigan PM, Klimas NG, et al. Delayed type hypersensitivity skin tests are an independent predictor of HIV disease progression. J Infect Dis. 1994;169:893-897.
20. Blatt SP, Hendrix CW, Butzin CA, et al. Delayed type hypersensitivity testing predicts progression to AIDS in HIV infected patients. Ann Intern Med. 1993;119:177-184.
21. Miller WC, Thielman NM, Swai N, et al. Delayed type hypersensitivity testing in Tanzanian adults with HIV infection. J Acquir Immune Defic Syndr. 1996;12:303-308.
22. Barkan SE, Melnick SL, Preston-Martin S, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology. 1998;9:117-125.
23. Lew J, Reichelderfer P, Fowler M, et al. Determinations of levels of human immunodeficiency virus type 1 RNA in plasma: reassessment of parameters affecting assay outcome. J Clin Microbiol. 1998;36:1471-1479.
24. Calvelli T, Denny T, Paxton H, et al. Guidelines for flow cytometric immunophenotyping. Cytometry. 1993;14:702-715.
25. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41: 1-19.
26. Carr A, Chuah J, Hudson J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS. 2000;14:1171-1180.
27. Valdez H, Smith KY, Landay A, et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS. 2000;14:11-21.
28. French MA, Cameron PU, Grimsley G, et al. Correction of human immunodeficiency virus-associated depression of delayed-type hypersensitivity (DTH) after zidovudine therapy: DTH, CD4+ T-cell numbers, and epidermal Langerhans cell density are independent variables. Clin Immunol Immunopathol. 1990;55:86-96.
29. Shell-Duncan B, Wood JW. The evaluation of delayed-type hypersensitivity responsiveness and nutritional status as predictors of gastrointestinal and acute respiratory infection: a prospective field study among traditional nomadic Kenyan children. J Trop Pediatr. 1997;43:25-32.
30. Smith SM, Levy NS, Hayes CE. Impaired immunity in vitamin A-deficient mice. J Nutr. 1987;117:857-865.
31. Rall LC, Meydani SN. Vitamin B6 and immune competence. Nutr Rev. 1993;51:217-225.
32. Kukreja R, Khan A. Effect of selenium deficiency and its supplementation on DTH response, antibody forming cells and antibody titre. Indian J Exp Biol. 1998;36:203-205.
33. Matarese G. Leptin and the immune system: how nutritional status influences the immune response. Eur Cytokine Netw. 2000;11:7-14.
34. Chin DP, Osmond D, Page-Shafer K, et al. Reliability of anergy skin testing in the person with HIV infection. Am J Respir Crit Care Med. 1996; 153:1982-1984.
35. Caiaffa WT, Graham NM, Galai N, et al. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med. 1995;155:2111-2117.
36. Klein RS, Sobel J, Flanigan T, et al. Stability of cutaneous anergy in women with or at risk for HIV infection. HIV Epidemiology Research Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20: 238-244.
37. Pouchot J, Grasland A, Collet C, et al. Reliability of tuberculin skin test measurement. Ann Intern Med. 1997;126:210-214.